# Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B

> **NCT04069858** · PHASE4 · UNKNOWN · sponsor: **Korea University** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Switching to Generic Entecavir (Baracle®)

## Key facts

- **NCT ID:** NCT04069858
- **Lead sponsor:** Korea University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069858, "Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04069858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*